Unapproved Zika Tests Attract FDA 'Untitled' Letters
This article was originally published in The Gray Sheet
Two companies and two hospitals are marketing Zika virus diagnostics without FDA go-ahead, the agency said in letters that asked the organizations for data supporting their assays.
You may also be interested in...
Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?
US FDA hits firms in New Jersey, South Korea and China with warning letters. Meanwhile, Catalent and several outsourcing facilities work on Form 483 inspection findings as Mylan, Viona and Lohxa announce drug recalls.
The median review time for novel agents at CDER hasn’t changed in five years. Our infographic offers a look at the tortoises and hares (all of them winners because they got approved).